Inflammatory bowel disease: Therapeutic limitations and prospective of the stem cell therapy
Authors:
Open Access
- 26 October 2020
- journal article
- review article
- Published by Baishideng Publishing Group Inc. in World Journal of Stem Cells
- Vol. 12 (10) , 1050-1066
Abstract
Inflammatory bowel disease: Therapeutic limitations and prospective of the stem cell therapyKeywords
This publication has 117 references indexed in Scilit:
- Harnessing the Mesenchymal Stem Cell Secretome for the Treatment of Cardiovascular DiseaseCell Stem Cell, 2012
- Mesenchymal Stem/Stromal Cells (MSCs): Role as Guardians of InflammationMolecular Therapy, 2012
- Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47Nature Genetics, 2011
- Function of the intestinal epithelium and its dysregulation in inflammatory bowel diseaseInflammatory Bowel Diseases, 2011
- Paneth cells constitute the niche for Lgr5 stem cells in intestinal cryptsNature, 2010
- Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility lociNature Genetics, 2010
- Hematopoietic stem cell: self‐renewal versus differentiationWIREs Mechanisms of Disease, 2010
- Mucosal Healing in Inflammatory Bowel Disease: Results From a Norwegian Population-Based CohortGastroenterology, 2007
- Interferon-γ does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cellsClinical and Experimental Immunology, 2007
- Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statementCytotherapy, 2006